View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 15, 2022

OxDX raises funding for rapid diagnostic technology development

The technology combines new universal labelling technology and machine learning analysis to detect specific pathogens.

Oxford University spin-out company OxDX has raised £2.6m in pre-seed funding for the development of artificial intelligence (AI)-powered rapid diagnostic technology.

Ahren Innovation Capital and IQ Capital co-led the initial funding, which also saw participation from Science Creates Ventures.

OxDX intends to use the funds to expand its team and work with development partners to further validate the technology.

The company’s rapid diagnostic technology can detect and recognise specific species and strains of bacteria, viruses and other pathogens in a sample.

It combines new universal labelling technology and machine learning analysis in a neural network to identify the specific pathogens that cause infection in only a few seconds.

The company stated that the technology aims to improve the cost, speed and accuracy of infectious disease diagnosis.

OxDX CEO Alex Batchelor said: “Our ability to take a sample from someone with an unknown infection and answer the open question ‘what do they have?’ within a minute is a gamechanger for infection diagnosis and treatment.

“We’ll start with respiratory viruses and expand from there. In parallel, we’ll be simplifying the workflow to move the test from the lab to point of care, which will represent a step-change in the availability and cost of infectious disease diagnostics worldwide.”

The company has said that the technology can detect respiratory viruses in clinical samples, as well as directly identify the strain in the case of Covid-19 and influenza viruses.

OxDX aims to develop a new analysis platform that can quickly scale many diseases through software updates.

Related Companies

Free Report

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy